Literature DB >> 15275645

uPA and uPAR in fibrinolysis, immunity and pathology.

Anna Mondino1, Francesco Blasi.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 15275645     DOI： 10.1016/j.it.2004.06.004

Source DB:  PubMed          Journal:  Trends Immunol        ISSN： 1471-4906            Impact factor:   16.687


× No keyword cloud information.
  102 in total

1.  Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects.

Authors:  Manfred Schmitt; Karin Mengele; Apostolos Gkazepis; Rudolf Napieralski; Viktor Magdolen; Ute Reuning; Nadia Harbeck
Journal:  Breast Care (Basel)       Date:  2008-10-15       Impact factor: 2.860

2.  Antagonistic anti-urokinase plasminogen activator receptor (uPAR) antibodies significantly inhibit uPAR-mediated cellular signaling and migration.

Authors:  Sai Duriseti; David H Goetz; Daniel R Hostetter; Aaron M LeBeau; Ying Wei; Charles S Craik
Journal:  J Biol Chem       Date:  2010-05-25       Impact factor: 5.157

3.  High molecular weight kininogen binds phosphatidylserine and opsonizes urokinase plasminogen activator receptor-mediated efferocytosis.

Authors:  Aizhen Yang; Jihong Dai; Zhanli Xie; Robert W Colman; Qingyu Wu; Raymond B Birge; Yi Wu
Journal:  J Immunol       Date:  2014-03-31       Impact factor: 5.422

4.  Tumor necrosis factor alpha modulates the dynamics of the plasminogen-mediated early interaction between Bifidobacterium animalis subsp. lactis and human enterocytes.

Authors:  Manuela Centanni; Simone Bergmann; Silvia Turroni; Sven Hammerschmidt; Gursharan Singh Chhatwal; Patrizia Brigidi; Marco Candela
Journal:  Appl Environ Microbiol       Date:  2012-01-27       Impact factor: 4.792

5.  Structural basis of interaction between urokinase-type plasminogen activator and its receptor.

Authors:  Cyril Barinka; Graham Parry; Jennifer Callahan; David E Shaw; Alice Kuo; Khalil Bdeir; Douglas B Cines; Andrew Mazar; Jacek Lubkowski
Journal:  J Mol Biol       Date:  2006-08-26       Impact factor: 5.469

6.  Circulating soluble urokinase plasminogen activator receptor levels and peripheral arterial disease outcomes.

Authors:  Ayman Samman Tahhan; Salim S Hayek; Pratik Sandesara; Jamal Hajjari; Muhammad Hammadah; Wesley T O'Neal; Heval M Kelli; Ayman Alkhoder; Nima Ghasemzadeh; Yi-An Ko; Hiroshi Aida; Mohamad Mazen Gafeer; Naser Abdelhadi; Kareem Hosny Mohammed; Keyur Patel; Shipra Arya; Jochen Reiser; Viola Vaccarino; Laurence Sperling; Arshed Quyyumi
Journal:  Atherosclerosis       Date:  2017-06-08       Impact factor: 5.162

7.  The pro-inflammatory biomarker soluble urokinase plasminogen activator receptor (suPAR) is associated with incident type 2 diabetes among overweight but not obese individuals with impaired glucose regulation: effect modification by smoking and body weight status.

Authors:  A Heraclides; T M Jensen; S S Rasmussen; J Eugen-Olsen; S B Haugaard; K Borch-Johnsen; A Sandbæk; T Lauritzen; D R Witte
Journal:  Diabetologia       Date:  2013-04-24       Impact factor: 10.122

Review 8.  Effect of feeding regimens on circadian rhythms: implications for aging and longevity.

Authors:  Oren Froy; Ruth Miskin
Journal:  Aging (Albany NY)       Date:  2010-12-11       Impact factor: 5.682

Review 9.  VEGF-initiated angiogenesis and the uPA/uPAR system.

Authors:  Johannes M Breuss; Pavel Uhrin
Journal:  Cell Adh Migr       Date:  2012-10-17       Impact factor: 3.405

10.  Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients.

Authors:  H Taubert; P Würl; T Greither; M Kappler; M Bache; C Lautenschläger; S Füssel; A Meye; A W Eckert; H-J Holzhausen; V Magdolen; M Kotzsch
Journal:  Br J Cancer       Date:  2010-01-05       Impact factor: 7.640
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.